
    
      Weekly ADI-PEG 20 will be cohort dose escalated (18, 27 and 36 mg/m2), with pemetrexed 500
      mg/m2 and cisplatin 75 mg/m2 both given every 3 weeks. Subjects may receive a maximum of 6,
      3-week cycles of ADIPemCis for a total of 18 weeks of treatment. Subjects with NSCLC may
      receive 4 to 6, 3-week cycles as per local institutional policy. Those subjects completing
      ADIPemCis treatment may continue on ADI-PEG 20 monotherapy if they have SD or better.
      Subjects with NSCLC may continue to receive pemetrexed as per local institutional policy
      along with ADI-PEG 20 and/or continue on ADI-PEG 20 monotherapy after pemetrexed is also
      discontinued.
    
  